SkinBioTherapeutics (LON:SBTX) Hits New 1-Year High – Should You Buy?

SkinBioTherapeutics plc (LON:SBTX)’s share price reached a new 52-week high during trading on Monday . The stock traded as high as GBX 20 ($0.25) and last traded at GBX 20 ($0.25), with a volume of 1041299 shares trading hands. The stock had previously closed at GBX 17.98 ($0.23).

SkinBioTherapeutics Stock Up 11.2 %

The company has a debt-to-equity ratio of 27.57, a current ratio of 0.93 and a quick ratio of 10.01. The stock has a market capitalization of £45.69 million, a P/E ratio of -12.30 and a beta of 2.01. The firm has a 50-day simple moving average of GBX 17.49 and a 200 day simple moving average of GBX 14.92.

SkinBioTherapeutics (LON:SBTX) last issued its quarterly earnings data on Wednesday, December 4th. The company reported GBX (1.54) (($0.02)) earnings per share (EPS) for the quarter. SkinBioTherapeutics had a negative return on equity of 115.86% and a negative net margin of 237.95%.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.